Patent application number | Description | Published |
20080305994 | Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye - A composition for treating, reducing, ameliorating, alleviating, or preventing a dry eye condition or an opthalmologic disorder that has an etiology in inflammation comprises an inhibitor of activity of poly(ADP-ribose) polymerase (“PARP”). The composition can also include a modulator of pro-inflammatory gene expression. | 12-11-2008 |
20080306038 | Compositions and Methods for Modulating Inflammation Using Fluoroquinolones - Compositions for modulating an inflammation comprise a fluoroquinolone having one of Formulae I-VIII. Methods for modulating an inflammation comprise administering such compositions to a subject in need thereof. The compositions and methods are suitable for modulating an ocular or ophthalmic inflammation, including uveitis, vernal keratoconjunctivitis, or inflammation associated with contact lens-associated corneal infiltrates. | 12-11-2008 |
20090054406 | Compositions and Methods for Modulating Endophthalmitis Using Fluoroquinolones - Compositions for modulating endophthalmitis comprise a fluoroquinolone having one of Formulae I-VIII. Methods for modulating endophthalmitis comprise administering such compositions to a subject in need thereof. The compositions and methods are suitable for modulating post-operative endophthalmitis, post-traumatic endophthalmitis, non-infectious endophthalmitis, panophthalmitis, hematogenous endophthalmitis, or combinations thereof. | 02-26-2009 |
20110046033 | Multipurpose Lens Care Solution with Benefits to Corneal Epithelial Barrier Function - A multipurpose lens care solution comprising 0.005 wt. % to 1 wt. % of an anionic biopolymer, and an antimicrobial agent selected from 0.5 ppm to 2 ppm of poly(hexamethylene biguanide), 0.5 ppm to 2 ppm polyquaternium-1, or 1 ppm to 4 ppm alexidine. The lens care solution exhibits a ZO-1 immunostaining of HCEpiC similar to phosphate buffered saline for after thirty minutes of contact time with the solution. The lens care solution will also have a transepithelial electrical resistance (TEER) of HCEpiC within a 25% difference or less than phosphate buffered saline in Ohm/cm | 02-24-2011 |
20110166126 | Compositions and Methods for Modulating Endophthalmitis Using Fluoroquinolones - Compositions for modulating endophthalmitis comprise a fluoroquinolone having one of Formulae I-VIII. Methods for modulating endophthalmitis comprise administering such compositions to a subject in need thereof. The compositions and methods are suitable for modulating post-operative endophthalmitis, post-traumatic endophthalmitis, non-infectious endophthalmitis, panophthalmitis, hematogenous endophthalmitis, or combinations thereof. | 07-07-2011 |
20110269796 | Use of Levocabastine for Modulating Generation of Pro-Inflammatory Cytokines - A composition for modulating generation of pro-inflammatory cytokines comprises levocabastine or a pharmaceutically acceptable salt or ester thereof. Such composition is useful for treating or controlling diseases having an inflammatory component, such as ocular diseases that are caused by inflammation or have inflammatory sequelae. | 11-03-2011 |
20110281882 | Compositions and Methods for Treating, Controlling, Reducing, or Ameliorating Inflammatory Pain - A composition for treating, controlling, reducing, or ameliorating inflammatory pain comprises a dissociated glucocorticoid receptor agonist (“DIGRA”), a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof. The composition can comprise an additional anti-inflammatory agent and can be formulated for topical application, injection, or implantation. It may be used in a method of managing post-surgical ocular pain such that it has lower risk of eliciting adverse side effects seen with other therapeutic agents. | 11-17-2011 |
20120065228 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING OCULAR INFLAMMATORY WITH LOWER RISK OF INCREASED INTRAOCULAR PRESSURE - A composition for treating, controlling, reducing, or ameliorating inflammatory pain comprises a dissociated glucocorticoid receptor agonist (“DIGRA”), a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof. The composition can comprise an additional anti-inflammatory agent and can be formulated for topical application, injection, or implantation. It may be used in a method of managing ocular inflammation and/or pain such that it has lower risk of eliciting increased intraocular pressure seen with glucocorticoids. | 03-15-2012 |
20120070401 | Composition and Method for Promoting Wound Healing - A composition for promoting wound healing comprises a bioadhesive polymer and a pharmaceutically acceptable liquid medium. Such a composition is applied to a wound to promote healing of the wound. The bioadhesive polymer can be selected from the group consisting of natural or synthetic hydrophilic polymers and hydrogels. | 03-22-2012 |
20120252756 | Pharmaceutical Compositions and Methods for Treating, Controlling, Ameliorating, or Reversing Conditions of the Eye - A pharmaceutical composition comprises a polyethylene glycol having a molecular weight in the range from about 1,000 to about 10,000, and a water-soluble cellulose derivative having a molecular weight in the range from about 50,000 to 120,000. The composition can further comprise boric acid and/or phosphate, a non-ionic surfactant, and/or an ophthalmic therapeutic agent. The composition is effective in treating, controlling, ameliorating, or reversing one or more conditions or symptoms of dry eye. | 10-04-2012 |
20120316199 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFLAMMATORY PAIN - A composition for treating, controlling, reducing, or ameliorating inflammatory pain comprises a dissociated glucocorticoid receptor agonist (“DIGRA”), a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof. The composition can comprise an additional anti-inflammatory agent and can be formulated for topical application, injection, or implantation. It may be used in a method of managing post-surgical ocular pain such that it has lower risk of eliciting adverse side effects seen with other therapeutic agents. | 12-13-2012 |
20130289070 | Use of Levocabastine for Modulating Generation of Pro-Inflammatory Cytokines - A composition for modulating generation of pro-inflammatory cytokines comprises levocabastine or a pharmaceutically acceptable salt or ester thereof. Such composition is useful for treating or controlling diseases having an inflammatory component, such as ocular diseases that are caused by inflammation or have inflammatory sequelae. | 10-31-2013 |
20130345259 | Use of Levocabastine for Modulating Generation of Pro-Inflammatory Cytokines - A composition for modulating generation of pro-inflammatory cytokines comprises levocabastine or a pharmaceutically acceptable salt or ester thereof. Such composition is useful for treating or controlling diseases having an inflammatory component, such as ocular diseases that are caused by inflammation or have inflammatory sequelae. | 12-26-2013 |